Clinical Trials · NCT06023095
A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 24
- Start date
- Sep 2023
- Locations
- 3 sites, China
- Primary endpoint
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration